Forgot your password?
BNT111 in combination with Libtayo previously received fast track designation from the US Food and Drug Administration
The regulator is also reviewing the IL-31 inhibitor as a treatment for atopic dermatitis
The IL-13 inhibitor can now be used to treat adults and adolescents who are candidates for systemic therapy
The inflammatory disease can lead to complications including multisystem organ failure and sepsis
The oral JAK inhibitor is designed to interrupt the pathways that are thought to contribute to hair loss
The JAK inhibitor has been recommended for patients who have had an inadequate response to, or have not been advised, topical corticosteroids
Approximately 10% of all melanoma cases in the UK are diagnosed at more advanced stages
The PDE4 inhibitor is already approved in the US to treat seborrhoeic dermatitis and plaque psoriasis
Almost 77% of patients have reported that the condition negatively affects their daily activities and well-being
The precancerous condition has an estimated prevalence of 13.3% in Europe